Abstract
The Transition to Dolutegravir-Based Regimens in the Presence of High- Level Drug Resistance to Nucleotide Reverse Transcriptase Inhibitors: Does It Deserve More Attention?
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
